Ifosfamide-Induced Metabolic Encephalopathy in 2 Patients With Cutaneous T-Cell Lymphoma Successfully Treated With Methylene Blue.
Ifosfamide-Induced Metabolic Encephalopathy in 2 Patients With Cutaneous T-Cell Lymphoma Successfully Treated With Methylene Blue.
- 2018
Ifosfamide, an alkylating agent used in cancer treatments, can cause neurotoxicity. The clinical presentation can range from mild symptoms such as acute confusion to non-convulsive seizures, severe irreversible coma, and death. The benefit of methylene blue use in treating ifosfamide-induced metabolic encephalopathy is not well established. In this article, we present 2 cases of ifosfamide-induced metabolic encephalopathy responsive to methylene blue treatment.
English
2324-7096
10.1177_2324709618786769 [pii] 10.1177/2324709618786769 [doi] PMC6069036 [pmc]
IN PROCESS -- NOT YET INDEXED
MedStar Washington Hospital Center
Washington Cancer Institute
Medicine/Internal Medicine
Journal Article
Ifosfamide, an alkylating agent used in cancer treatments, can cause neurotoxicity. The clinical presentation can range from mild symptoms such as acute confusion to non-convulsive seizures, severe irreversible coma, and death. The benefit of methylene blue use in treating ifosfamide-induced metabolic encephalopathy is not well established. In this article, we present 2 cases of ifosfamide-induced metabolic encephalopathy responsive to methylene blue treatment.
English
2324-7096
10.1177_2324709618786769 [pii] 10.1177/2324709618786769 [doi] PMC6069036 [pmc]
IN PROCESS -- NOT YET INDEXED
MedStar Washington Hospital Center
Washington Cancer Institute
Medicine/Internal Medicine
Journal Article